REFERENCES

1. National Institute for Health and Care Excellence (NICE). Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management. Clinical guideline [CG154]. London: NICE; 2012. Available at: https://www.nice.org.uk/guidance/cg154.

2. Regan L. Miscarriage: early. In: Arulkumaran S, Regan L, Papageorghiou A, Monga A, Farquharson DIM (eds), Obstetrics and Gynaecology (Oxford Desk Reference Series), pp. 559-59. Oxford: Oxford University Press; 2011.

3. Regan L, Rai R. Epidemiology and the medical causes of miscar­riage. BaillieresBestPractRes Clin ObstetGynaecol 2000;14:839-54.

4. Arias-Stella J. Atypical endometrial changes produced by chori­onic tissue. Hum Pathol 1972;3:450-53.

5. Bigrigg MA, Read MD. Management of women referred to early pregnancy assessment unit: care and cost effectiveness. BMJ 1991;302:577-79.

6. Everett CB, Preece E. Women with bleeding in the first 20 weeks of pregnancy: value of general practice ultrasound in detecting fetal heart movement. Br J Gen Pract 1996;46:7-9.

7. Pearlstone M, Baxi L. Subchorionic hematoma: a review. Obstet Gynecol Surv 1993;48:65-68.

8. Tuuli MG, Norman SM, Odibo AO, Macones GA, Cahill AG. Perinatal outcomes in women with subchorionic hematoma. Obstet Gynecol 2011; 117:1205-12.

9. Konrad G. First-trimester bleeding with falling HCG: don't as­sume miscarriage Can Fam Physician 2007;53:831-32.

10. Nielsen S, Hahlin M. Expectant management of first-trimester spontaneous abortion. Lancet 1995;345:84-86.

11. Shelley JM, Healy D, Grover S. A randomised trial of surgical, medical and expectant management of first trimester spontan­eous miscarriage. AustN Z J Obstet Gynaecol 2005;45:122-27.

12. Sairam S, Khare M, Michailidis G, Thilaganathan B. The role of ultrasound in the expectant management of early pregnancy loss. Ultrasound Obstet Gynecol 2001;17:506-509.

13.

14. Trinder J, Brocklehurst P, Porter R, Read M, Vyas S, Smith L. Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ 2006;332:1235-40.

15. Conforti A, Alviggi C, Mollo A, De Placido G, Magos A. The man­agement of Asherman syndrome: a review of literature. Reprod Biol Endocrinol 2013;11:118.

16. Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev 2017;1:CD007223.

17. Bagratee JS, Khullar V, Regan L, Moodley J, Kagoro H. A random­ized controlled trial comparing medical and expectant manage­ment of first trimester miscarriage. Hum Reprod 2004;19:266-71.

18. Nanda K, Lopez LM, Grimes DA, Peloggia A, Nanda G. Expectant care versus surgical treatment for miscarriage. Cochrane Database Syst Rev 2012;3:CD003518.

19. Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 2013;99:63.

20. Zegers-Hochschild F, Adamson GD, de Mouzon J, et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril 2009;92:1520-24.

21. Kolte AM, Bernardi LA, Christiansen OB, et al. Terminology for pregnancy loss prior to viability: a consensus statement from the ESHRE early pregnancy special interest group. Hum Reprod 2015;30:495-98.

22. Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treat­ment of recurrent miscarriage. Hum Reprod 2006;21:2216-22.

23. ESHRE guideline: recurrent pregnancy loss Human Reproduction Open, pp. 1-12, 2018. doi:10.1093/hropen/hoy004.

24. Royal College of Obstetricians and Gynaecologists (RCOG).

25. Grande M, Borrell A, Garcia-Posada R, et al. The effect of ma­ternal age on chromosomal anomaly rate and spectrum in recur­rent miscarriage. Hum Reprod 2012;27:3109-17.

26. Lashen H, Fear K, Sturdee DW. Obesity is associated with in­creased risk of first trimester and recurrent miscarriage: matched case-control study. Hum Reprod 2004;19:1644-46.

27. Kolte AM, Olsen LR, Mikkelsen EM, Christiansen OB, Nielsen HS. Depression and emotional stress is highly prevalent among women with recurrent pregnancy loss. Hum Reprod 2015;30:777-82.

28. Gold KJ, Sen A, Hayward RA. Marriage and cohabitation out­comes after pregnancy loss. Pediatrics 2010:125:e1202-207.

29. Sugiura-Ogasawara M, Ozaki Y, Katano K, Suzumori N, Kitaori T, Mizutani E. Abnormal embryonic karyotype is the most frequent cause of recurrent miscarriage. Hum Reprod 2012;27:2297-303.

30. Ogasawara M, Aoki K, Okada S, Suzumori K. Embryonic karyo­type of abortuses in relation to the number of previous miscar­riages. Fertil Steril 2000;73:300-304.

31. Carp H, Toder V, Aviram A, Daniely M, Mashiach S, Barkai G. Karyotype of the abortus in recurrent miscarriage. Fertil Steril 2001:75:678-82.

32. Stephenson MD, Awartani KA, Robinson WP. Cytogenetic ana­lysis of miscarriages from couples with recurrent miscarriage: a case-control study. Hum Reprod 2002:17:446-51.

33. Foyouzi N, Cedars MI, Huddleston HG. Cost-effectiveness of cytogenetic evaluation of products of conception in the patient with a second pregnancy loss. Fertil Steril 2012:98:151-55.e3.

34. Kutteh WH. Novel strategies for the management of recurrent pregnancy loss. Semin Reprod Med 2015:33:161-68.

35. Barber JC, Cockwell AE, Grant E, Williams S, Dunn R, Ogilvie CM. Is karyotyping couples experiencing recurrent miscarriage worth the cost? BJOG 2010;117:885-88.

36. The Practice Committee ofthe American Society for Reproductive Medicine.

37. Lawn, AM, Wilson EW, Finn CA. The ultrastructure of human decidual and predecidual cells. J Reprod Fertil 1971;26:85-90.

38. Loke Y, King A. Human Implantation: Cell Biology and Immunology. Cambridge: Cambridge University Press; 1995.

39. Rosenfeld DL, Chudow S, Bronson RA. Diagnosis of luteal phase inadequacy. Obstet Gynecol 1980;56:193-96.

40. Wallach E, Jones GS. The luteal phase defect. Fertil Steril 1976;27:351-56.

41. Ke RW. Endocrine basis for recurrent pregnancy loss. Obstet Gynecol Clin North Am 2014;41:103-12.

42. LeVine L. Habitual abortion. a controlled study of progestational therapy. West J Surg Obstet Gynecol 1964;72:30.

43. Swyer G, Daley D. Progesterone implantation in habitual abor­tion. Br Med J 1953;1:1073.

44. Walch KT, Huber JC. Progesterone for recurrent miscar­riage: truth and deceptions. Best Pract Res Clin Obstet Gynaecol 2008;22:375-89.

45. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. BJOG 1989;96:275-80.

46. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2013;10:CD003511.

47. Carp H. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol 2015;31:422-30.

48. Coomarasamy A, Williams H, Truchanowicz E, et al. A random­ized trial of progesterone in women with recurrent miscarriages. N Engl J Med 2015;373:2141-48.

49. Ismail AM, Abbas AM, Ali MK, Amin AF. Peri-conceptional pro­gesterone treatment in women with unexplained recurrent mis­carriage: a randomized double-blind placebo-controlled trial. J Matern Fetal Neonatal Med 2018;31:388-94.

50. Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM 2001;94:435-44.

51. Vaarasmaki MS, Hartikainen A, Anttila M, Pramila S, Koivisto M.

52. Jovanovic L, Knopp RH, Kim H, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy. Diabetes Care 2005;28:1113.

53. Zolghadri J, Tavana Z, Kazerooni T, Soveid M, Taghieh M. Relationship between abnormal glucose tolerance test and his­tory of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study. Fertil Steril 2008;90:727-30.

54. Sagle M, Bishop K, Ridley N, et al. Recurrent early miscarriage and polycystic ovaries. BMJ 1988;297:1027-28.

55. Rai R, Backos M, Rushworth F, Regan L. Polycystic ovaries and re­current miscarriage—a reappraisal. Hum Reprod 2000;15:612-15.

56. Cocksedge KA, Li TC, Saravelos SH, Metwally M. A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage. Reprod Biomed Online 2008;17:151-60.

57. Liddell HS, Sowden K, Farquhar CM. Recurrent miscar­riage: screening for polycystic ovaries and subsequent pregnancy outcome. AustN Z J Obstet Gynaecol 1997;37:402-406.

58. Tulppala M, Stenman UH, Cacciatore B, Ylikorkala O. Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women. BJOG 1993;100:348-52.

59. Cocksedge KA, Saravelos SH, Wang Q, Tuckerman E, Laird SM, Li TC. Does free androgen index predict subsequent pregnancy outcome in women with recurrent miscarriage? Hum Reprod 2008;23:797-802.

60. Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hor­mone, infertility, and miscarriage. Lancet 1990;336:1141-44.

61. Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 1998;69:682-90.

62. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

63. Cocksedge KA, Saravelos SH, Metwally M, Li TC. How common is polycystic ovary syndrome in recurrent miscarriage? Reprod Biomed Online 2009;19:572-76.

64. Matjila MJ, Hoffman A, van der Spuy ZM. Medical conditions associated with recurrent miscarriage—is BMI the tip of the ice­berg? Eur J Obstet Gynecol Reprod Biol 2017;214:91-96.

65. Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, Minaguchi

H. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril 1998;70:246-52.

66. van den Boogaard E, Vissenberg R, Land JA, et al. Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity be­fore conception and in early pregnancy: a systematic review. Hum Reprod Update 2011;17:605-19.

67. Ticconi C, Giuliani E, Veglia M, Pietropolli A, Piccione E, Di Simone N. Thyroid autoimmunity and recurrent miscarriage. Am J Reprod Immunol 2011;66:452-59.

68. Boots CE, Stephenson MD. Does obesity increase the rate of mis­carriage in spontanous conception: a systematic review. Fertil Steril 2011;96 Suppl 3:S284.

69. Metwally M, Ong KJ, Ledger WL, Li TC. Does high body mass index increase the risk of miscarriage after spontaneous and as­sisted conception? A meta-analysis of the evidence. Fertil Steril 2008;90:714-26.

70. Metwally M, Saravelos SH, Ledger WL, Li TC. Body mass index and risk of miscarriage in women with recurrent miscarriage. Fertil Steril 2010;94:290-95.

71. Boots CE, Bernardi LA, Stephenson MD. Frequency of euploid miscarriage is increased in obese women with recurrent early pregnancy loss. Fertil Steril 2014;102:455-59.

72. Metwally M, Tuckerman EM, Laird SM, Ledger WL, Li TC. Impact of high body mass index on endometrial morphology and function in the peri-implantation period in women with recur­rent miscarriage. ReprodBiomed Online 2007;14:328-34.

73. Miyakis S, Lockshin MD, Atsumi T, et al. International con­sensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.

74. Lim W. Complement and the antiphospholipid syndrome. Curr Opin Hematol 2011;18:361-65.

75. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein

I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-23.

76. Bates SM. Consultative hematology: the pregnant patient preg­nancy loss. Hematology Am Soc Hematol Educ Program 2010;2010: 166-72.

77. Girardi G. Heparin treatment in pregnancy loss: potential thera­peutic benefits beyond anticoagulation. J Reprod Immunol 2005;66:45-51.

78. Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. BJOG 1999;106:102-107.

79. Kutteh WH. Antiphospholipid antibody-as sociated recur­rent pregnancy loss: treatment with heparin and low-dose as­pirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-89.

80. Mak A, Cheung MW, Cheak AA, Ho RC. Combination of hep­arin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti­phospholipid antibodies: a meta-analysis of randomized con­trolled trials and meta-regression. Rheumatology 2010;49:281-88.

81. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with re­current miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253.

82. Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010;115:4162.

83. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus hep­arin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010;362:1586-96.

84. de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev 2014;7:CD004734.

85. Foka ZJ, Lambropoulos AF, Saravelos H, et al. Factor V Leiden and prothrombin G20210A mutations, but not methylenete­trahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000;15:458-62.

86. Sarig G, Younis JS, Hoffman R, Lanir N, Blumenfeld Z, Brenner B. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002;77:342-47.

87. Carp H, Dolitzky M, Tur-Kaspa I, Inbal A. Hereditary thrombophilias are not associated with a decreased live birth rate in women with recurrent miscarriage. Fertil Steril 2002;78: 58-62.

88. Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 2002;17:1633-37.

89. Jivraj S, Rai R, Underwood J, Regan L. Genetic thrombophilic mu­tations among couples with recurrent miscarriage. Hum Reprod 2006;21:1161-65.

90. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901-908.

91. Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004;164:558-63.

92. Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of preg­nancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 2014;384:1673-83.

93. de Jong PG, Quenby S, Bloemenkamp KW, et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia-study protocol for a randomized controlled trial. Trials 2015;16:208.

94. Chan YY, Jayaprakasan K, Zamora J, et al. The prevalence of congenital uterine anomalies in unselected and high-ri sk populations: a systematic review. Hum Reprod Update 2011;17: 761-71.

95. Jaslow CR, Kutteh WH. Effect of prior birth and miscarriage frequency on the prevalence of acquired and congenital uterine anomalies in women with recurrent miscarriage: a cross-sectional study. Fertil Steril 2013;99:1916-22.e1.

96. Sugiura-Ogasawara M, Ozaki Y, Kitaori T, Kumagai K, Suzuki S. Midline uterine defect size is correlated with miscarriage of eu- ploid embryos in recurrent cases. Fertil Steril 2010;93:1983-88.

97. Salim R, Regan L, Woelfer B, Backos M, Jurkovic D. A compara­tive study of the morphology of congenital uterine anomalies in women with and without a history of recurrent first trimester miscarriage. Hum Reprod 2003;18:162-66.

98. Saravelos SH, Cocksedge KA, Li TC. The pattern of pregnancy loss in women with congenital uterine anomalies and recurrent miscarriage. Reprod Biomed Online 2010;20:416-22.

99. Kowalik CR, Goddijn M, Emanuel MH, et al. Metroplasty versus expectant management for women with recurrent mis­carriage and a septate uterus. Cochrane Database Syst Rev 2011;6:CD008576.

100. Saravelos SH, Cocksedge KA, Li TC. Prevalence and diagnosis of congenital uterine anomalies in women with reproductive failure: a critical appraisal. Hum Reprod Update 2008;14:415-29.

101. Drakeley AJ, Quenby S, Farquharson RG. Mid-trimester loss— appraisal of a screening protocol. Hum Reprod 1998;13:1975-80.

102. Rai R, Regan L Recurrent miscarriage. Lancet 2006;368:601-11.

103. Saravelos SH, Yan J, Rehmani H, Li TC. The prevalence and impact of fibroids and their treatment on the outcome of pregnancy in women with recurrent miscarriage. Hum Reprod 2011;26:3274-79.

104. Russo M, Suen M, Bedaiwy M, Chen I. Prevalence of uterine myomas among women with 2 or more recurrent pregnancy losses: a systematic review. J Minim Invasive Gynecol 2016;23:702-706.

105. Bailey AP, Jaslow CR, Kutteh WH. Minimally invasive surgical options for congenital and acquired uterine factors associated with recurrent pregnancy loss. Womens Health 2015;11:161-67.

106. Mukhopadhaya N, Pokuah Asante G, Manyonda IT. Uterine fi­broids: impact on fertility and pregnancy loss. Obstet Gynaecol Reprod Med 2007; 17:311-17.

107. Christiansen OB. Recurrent miscarriage is a useful and valid clin­ical concept. Acta Obstet Gynecol Scand 2014;93:852-57.

108. Field K, Murphy DJ. Perinatal outcomes in a subsequent pregnancy among women who have experienced recur­rent miscarriage: a retrospective cohort study. Hum Reprod 2015;30:1239-45.